Novartis India Managing Director Ranjit Shahani told India's PTI that the drugmaker expects upgrades at two Sandoz plants that were issued a warning letter by the FDA to soon be back to full production. We have already taken remedial action at these plants and these units would be soon back to normal," he told the news service. Novartis ($NVS) CEO Joseph Jimenez acknowledged during the Q3 earnings call last month that the FDA issued the warning letter for the sites in Kalwe as well as one in Turbhe, a plant that Sandoz intends to close. Story | More